Pith. sign in

Paper Citation Record · LEDGER

Visualisation of multi-indication randomised control trial evidence to support decision-making in oncology: a case study on bevacizumab

As of 11 August 2026, this Paper Citation Record lists 81 of 81 outbound references and 0 inbound Pith citation observations for arXiv:2501.08744.

A citation records a reference. It does not transfer a finding from one paper to another.

pith.paper-citation-record.v1
2501.08744 v1

Coverage vector

measured 81 of 81 reference resolution

Typed states for the displayed outbound observations.

Source: paper_references, paper_reference_links, observed 2026-08-10T20:22:00.646949Z

measured 81 of 81 standing notices

One-hop event checks from named stored sources.

Source: scholarly_work_events, retraction_status_cache, observed 2026-08-11T06:34:44.6726+00:00

measured 0 of 0 inbound itemization

Pith citing papers itemized under the disclosed page cap.

Source: paper_references, paper_reference_links

measured 0 of 1 external citation measurements

A source-named dated measurement, never combined with another source.

Source: cited_works

Reference resolution

81 of 81 outbound references displayed

  • verified exact62
  • verified fuzzy6
  • unresolved7
  • parse uncertain0
  • malformed identifier5
  • metadata mismatch1

External citation measurements

No source-named external measurement is stored.

Outbound references

Observation d563f134-2bf1-40d2-9394-83463f20a8a6 · outbound

This paper cites an unresolved cited work.

Visualisation of multi-indication randomised control trial evidence to support decision-making in oncology: a case study on bevacizumab Unresolved cited work

Reference 1

Resolution
unresolved
raw_fallback, observed 2026-08-10T20:22:01.740946Z

Source-reported events for the cited work

No event found in the named queried sources as of 2026-08-11T06:34:44.6726+00:00.

source=pdf_text observed=2026-08-10T20:22:00.393878Z digest=sha256:4d001207726603cdb25a092c4a0bb501a2de9d5c45294f91d597cf4f94d6d396

Observation f224a5b4-9d3e-48fb-b748-df200357e96e · outbound

This paper cites This common/pooled RTE is assigned a vague normal prior distribution, ~ (0,1000)dN.

Visualisation of multi-indication randomised control trial evidence to support decision-making in oncology: a case study on bevacizumab This common/pooled RTE is assigned a vague normal prior distribution, ~ (0,1000)dN

Reference 2

Resolution
verified fuzzy
raw_fallback, observed 2026-08-10T20:22:01.729326Z

Source-reported events for the cited work

No event found in the named queried sources as of 2026-08-11T06:34:44.6726+00:00.

source=pdf_text observed=2026-08-10T20:22:00.397661Z digest=sha256:9d535fd90548a8b0fe06b976c366bc1d110018c385f9c91b5d42596eabc114d3

Observation c9f65e27-d52a-4e76-ae54-148af1c0c2b4 · outbound

This paper cites The pooled parameter dm is assigned a vague normal prior distribution and a weakly informative half-normal prior distribution is assigned to the standard deviation, d.

Visualisation of multi-indication randomised control trial evidence to support decision-making in oncology: a case study on bevacizumab The pooled parameter dm is assigned a vague normal prior distribution and a weakly informative half-normal prior distribution is assigned to the standard deviation, d

Reference 3

Resolution
malformed identifier
raw_fallback, observed 2026-08-10T20:22:01.717485Z

Source-reported events for the cited work

No event found in the named queried sources as of 2026-08-11T06:34:44.6726+00:00.

source=pdf_text observed=2026-08-10T20:22:00.401515Z digest=sha256:6f87379212a3e315b7e9f9e49b4ba3b1408e469bbae5a158a78f913f2179ea07

Observation bbe61f6f-7cfa-434d-bf15-02c280f4f470 · outbound

This paper cites an unresolved cited work.

Visualisation of multi-indication randomised control trial evidence to support decision-making in oncology: a case study on bevacizumab Unresolved cited work

Reference 4

Resolution
verified exact
doi, observed 2026-08-10T20:22:00.819844Z

Source-reported events for the cited work

No event found in the named queried sources as of 2026-08-11T06:34:44.6726+00:00.

source=pdf_text observed=2026-08-10T20:22:00.417639Z digest=sha256:aeba886133ecbde461aeab7ec01e61a5ace238f690a9fdde7bb2d0b3dce77fad

Observation 506868eb-6d7f-45c1-a854-e1bf862890d9 · outbound

This paper cites an unresolved cited work.

Visualisation of multi-indication randomised control trial evidence to support decision-making in oncology: a case study on bevacizumab Unresolved cited work

Reference 5

Resolution
verified exact
doi, observed 2026-08-10T20:22:00.809145Z

Source-reported events for the cited work

No event found in the named queried sources as of 2026-08-11T06:34:44.6726+00:00.

source=pdf_text observed=2026-08-10T20:22:00.421413Z digest=sha256:13c0826af2b6a625caa932a7f9f8b4fdeb6bfc5fa9dc2f82fe3a41a730c4be6f

Observation 94fcd6f2-f4c6-4e27-b2cc-aca4363f8e75 · outbound

This paper cites an unresolved cited work.

Visualisation of multi-indication randomised control trial evidence to support decision-making in oncology: a case study on bevacizumab Unresolved cited work

Reference 6

Resolution
verified exact
doi, observed 2026-08-10T20:22:00.798852Z

Source-reported events for the cited work

No event found in the named queried sources as of 2026-08-11T06:34:44.6726+00:00.

source=pdf_text observed=2026-08-10T20:22:00.425199Z digest=sha256:d40406fac54e12d3943697ab6ce728614611c62eb4b9ad2c0b0c94917ee698d3

Observation a54fecb0-d673-4a41-8f8f-a090da3d302a · outbound

This paper cites Biomarker results from the A V ADO phase 3 trial of first- line bevacizumab plus docetaxel for HER2-negative metastatic breast cancer.

Visualisation of multi-indication randomised control trial evidence to support decision-making in oncology: a case study on bevacizumab Biomarker results from the A V ADO phase 3 trial of first- line bevacizumab plus docetaxel for HER2-negative metastatic breast cancer

Reference 7

Resolution
verified exact
doi, observed 2026-08-10T20:22:00.788297Z

Source-reported events for the cited work

No event found in the named queried sources as of 2026-08-11T06:34:44.6726+00:00.

source=pdf_text observed=2026-08-10T20:22:00.429124Z digest=sha256:871d6334c2adab15b15206c80042e4813a0b4f69033e0de3ee21ae9931f0d891

Observation 143ca053-4a17-4750-afc9-d03c3a850c33 · outbound

This paper cites an unresolved cited work.

Visualisation of multi-indication randomised control trial evidence to support decision-making in oncology: a case study on bevacizumab Unresolved cited work

Reference 8

Resolution
verified exact
doi, observed 2026-08-10T20:22:00.775893Z

Source-reported events for the cited work

No event found in the named queried sources as of 2026-08-11T06:34:44.6726+00:00.

source=pdf_text observed=2026-08-10T20:22:00.432840Z digest=sha256:9f4be0bf51f0fdc847a2479788072898739baee950235c7818f3f5665fa4307c

Observation 87451710-3c93-48e9-a476-a087dfe8620c · outbound

This paper cites Sunitinib plus paclitaxel versus bevacizumab plus paclitaxel for first-line treatment of patients with advanced breast cancer: A phase III, randomized, open-label trial.

Visualisation of multi-indication randomised control trial evidence to support decision-making in oncology: a case study on bevacizumab Sunitinib plus paclitaxel versus bevacizumab plus paclitaxel for first-line treatment of patients with advanced breast cancer: A phase III, randomized, open-label trial

Reference 9

Resolution
verified exact
doi, observed 2026-08-10T20:22:00.764936Z

Source-reported events for the cited work

correction dated 2011-08-03. Source: crossref record 10.1016/j.clbc.2011.06.004->10.1016/j.clbc.2011.03.005:correction, observed 2026-07-11T03:12:43.466735+00:00. This notice travels one citation hop only.

source=pdf_text observed=2026-08-10T20:22:00.437102Z digest=sha256:45eade015b7de382225b66ff9ca5d5cab3fd15b8e96db9a24c53ff247c17ab3b

Observation 9d1dd3bd-82b6-4e0d-9192-5535340d2e35 · outbound

This paper cites an unresolved cited work.

Visualisation of multi-indication randomised control trial evidence to support decision-making in oncology: a case study on bevacizumab Unresolved cited work

Reference 10

Resolution
verified exact
doi, observed 2026-08-10T20:22:00.752191Z

Source-reported events for the cited work

correction dated 2011-08-02. Source: crossref record 10.1016/s1470-2045(11)70205-4->10.1016/s1470-2045(11)70037-7:correction, observed 2026-07-11T03:17:45.890087+00:00. This notice travels one citation hop only.

source=pdf_text observed=2026-08-10T20:22:00.440852Z digest=sha256:1fd5d0b355e9354ad06c8219780ac829ddf1eb5ca274fbd886fbb73f5b08f92f

Observation 6f697f93-70e5-471f-8553-a5cf184f4d02 · outbound

This paper cites Phase III trial evaluating the addition of bevacizumab to endocrine therapy as first-line treatment for advanced breast cancer: the letrozole/fulvestrant and avastin (LEA) study.

Visualisation of multi-indication randomised control trial evidence to support decision-making in oncology: a case study on bevacizumab Phase III trial evaluating the addition of bevacizumab to endocrine therapy as first-line treatment for advanced breast cancer: the letrozole/fulvestrant and avastin (LEA) study

Reference 11

Resolution
verified exact
doi, observed 2026-08-10T20:22:00.740392Z

Source-reported events for the cited work

No event found in the named queried sources as of 2026-08-11T06:34:44.6726+00:00.

source=pdf_text observed=2026-08-10T20:22:00.444960Z digest=sha256:5582b6f51669bd76141a8045d9b57625f910e306aaf931266105d349ebbb4060

Observation b9496b2c-7590-4ce3-b56b-81b8fb34790e · outbound

This paper cites an unresolved cited work.

Visualisation of multi-indication randomised control trial evidence to support decision-making in oncology: a case study on bevacizumab Unresolved cited work

Reference 12

Resolution
verified exact
doi, observed 2026-08-10T20:22:00.727640Z

Source-reported events for the cited work

No event found in the named queried sources as of 2026-08-11T06:34:44.6726+00:00.

source=pdf_text observed=2026-08-10T20:22:00.448740Z digest=sha256:f072edbfdf23bc7ca2a64c1b3a3f707bb790e18b905877c7028ce4a453a9137c

Observation bbbc6bec-fd8f-4fd1-bd12-86f9f0c7c851 · outbound

This paper cites an unresolved cited work.

Visualisation of multi-indication randomised control trial evidence to support decision-making in oncology: a case study on bevacizumab Unresolved cited work

Reference 13

Resolution
unresolved
raw_fallback, observed 2026-08-10T20:22:01.705821Z

Source-reported events for the cited work

No event found in the named queried sources as of 2026-08-11T06:34:44.6726+00:00.

source=pdf_text observed=2026-08-10T20:22:00.452440Z digest=sha256:64c533500490d493baceae6f7dbc83c99429604eb4e2418aec30a58690c0b741

Observation 474d4a03-f840-4833-b3eb-dd68048ef2d1 · outbound

This paper cites an unresolved cited work.

Visualisation of multi-indication randomised control trial evidence to support decision-making in oncology: a case study on bevacizumab Unresolved cited work

Reference 15

Resolution
verified exact
doi, observed 2026-08-10T20:22:01.480166Z

Source-reported events for the cited work

No event found in the named queried sources as of 2026-08-11T06:34:44.6726+00:00.

source=pdf_text observed=2026-08-10T20:22:00.459986Z digest=sha256:a9be7a5ceb24a57ed9daf4f044a57dfbbdb930964682ef42528774cd63bc25cf

Observation 465b5e09-69a4-473b-8ba3-14daaa64c38e · outbound

This paper cites an unresolved cited work.

Visualisation of multi-indication randomised control trial evidence to support decision-making in oncology: a case study on bevacizumab Unresolved cited work

Reference 16

Resolution
verified exact
doi, observed 2026-08-10T20:22:01.470146Z

Source-reported events for the cited work

No event found in the named queried sources as of 2026-08-11T06:34:44.6726+00:00.

source=pdf_text observed=2026-08-10T20:22:00.463385Z digest=sha256:6efbdbc4b1c3bd145a1dcecc3ce021db888565ce0616eacf8207669a8803e1ea

Observation 27263ccb-c647-441d-afa1-ffb4a141c66c · outbound

This paper cites Improved survival with bevacizumab in advanced cervical cancer.

Visualisation of multi-indication randomised control trial evidence to support decision-making in oncology: a case study on bevacizumab Improved survival with bevacizumab in advanced cervical cancer

Reference 17

Resolution
verified exact
doi, observed 2026-08-10T20:22:01.458992Z

Source-reported events for the cited work

No event found in the named queried sources as of 2026-08-11T06:34:44.6726+00:00.

source=pdf_text observed=2026-08-10T20:22:00.467135Z digest=sha256:2672c4f65e54022d29ee3f38be43af01dcf96ee263404cbb8857700d74e2a5b3

Observation 1407a4fc-3044-4d94-ab6b-aebd6342f4c8 · outbound

This paper cites an unresolved cited work.

Visualisation of multi-indication randomised control trial evidence to support decision-making in oncology: a case study on bevacizumab Unresolved cited work

Reference 18

Resolution
malformed identifier
no resolver link, observed 2026-08-10T20:22:00.470736Z

Source-reported events for the cited work

Unavailable: canonical work link unavailable.

source=pdf_text observed=2026-08-10T20:22:00.470736Z digest=sha256:5155f9779704ab0ac79e8fd61fbb4d474ce3adc01e9bd5f653d180b516a00ffd

Observation 533af837-8f09-45a4-b438-976ac6f9079a · outbound

This paper cites Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer.

Visualisation of multi-indication randomised control trial evidence to support decision-making in oncology: a case study on bevacizumab Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer

Reference 19

Resolution
verified exact
doi, observed 2026-08-10T20:22:01.435165Z

Source-reported events for the cited work

No event found in the named queried sources as of 2026-08-11T06:34:44.6726+00:00.

source=pdf_text observed=2026-08-10T20:22:00.474470Z digest=sha256:88c168472162f37cc239d769d4886ba60146943d85d844e473912ff54a90bd6b

Observation 284b8049-3ffd-4983-b9bf-6456fd30bf58 · outbound

This paper cites Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial.

Visualisation of multi-indication randomised control trial evidence to support decision-making in oncology: a case study on bevacizumab Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial

Reference 20

Resolution
verified exact
doi, observed 2026-08-10T20:22:01.422927Z

Source-reported events for the cited work

No event found in the named queried sources as of 2026-08-11T06:34:44.6726+00:00.

source=pdf_text observed=2026-08-10T20:22:00.477936Z digest=sha256:cf2cdad4dd8ebd7563d2d1ee2c80b75e0ee781b7c1d69bf9ee0e6c189fe1b716

Observation 80402f93-7729-4943-929d-409aa314679a · outbound

This paper cites Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.

Visualisation of multi-indication randomised control trial evidence to support decision-making in oncology: a case study on bevacizumab Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

Reference 21

Resolution
verified exact
doi, observed 2026-08-10T20:22:01.411108Z

Source-reported events for the cited work

No event found in the named queried sources as of 2026-08-11T06:34:44.6726+00:00.

source=pdf_text observed=2026-08-10T20:22:00.481450Z digest=sha256:4fb290e4330e83aa17c6e9275e4f07f2925c39740d9b86c6900eb33e0252f5d2

Observation c5f8d6fa-cd0a-4845-a2d9-f3333b95ac2e · outbound

This paper cites an unresolved cited work.

Visualisation of multi-indication randomised control trial evidence to support decision-making in oncology: a case study on bevacizumab Unresolved cited work

Reference 22

Resolution
verified exact
doi, observed 2026-08-10T20:22:01.398942Z

Source-reported events for the cited work

No event found in the named queried sources as of 2026-08-11T06:34:44.6726+00:00.

source=pdf_text observed=2026-08-10T20:22:00.484988Z digest=sha256:62f76d5c7aaeff455c7f1e264e55095d5de8b65227128279c6cb86190795bcff

Observation fd9b26fd-c938-4242-92f6-1d928678583f · outbound

This paper cites Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.

Visualisation of multi-indication randomised control trial evidence to support decision-making in oncology: a case study on bevacizumab Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study

Reference 23

Resolution
verified exact
doi, observed 2026-08-10T20:22:01.387409Z

Source-reported events for the cited work

No event found in the named queried sources as of 2026-08-11T06:34:44.6726+00:00.

source=pdf_text observed=2026-08-10T20:22:00.488666Z digest=sha256:a41956a2d9d10bd9620934c84e726ef439962a3305bd79eb4f194c39084c72f9

Observation 72d62f28-fdcf-426a-bbb3-314dc3c6fc47 · outbound

This paper cites XELOX vs FOLFOX-4 as first-line therapy for metastatic colorectal cancer: NO16966 updated results.

Visualisation of multi-indication randomised control trial evidence to support decision-making in oncology: a case study on bevacizumab XELOX vs FOLFOX-4 as first-line therapy for metastatic colorectal cancer: NO16966 updated results

Reference 24

Resolution
verified exact
doi, observed 2026-08-10T20:22:01.376226Z

Source-reported events for the cited work

No event found in the named queried sources as of 2026-08-11T06:34:44.6726+00:00.

source=pdf_text observed=2026-08-10T20:22:00.491921Z digest=sha256:4531c1a63276dc71432e06839e9f2807b5e0be10f683a723796ef9eaca9d8788

Observation af7c4c0d-f3fa-41bf-892a-ca58036b134c · outbound

This paper cites an unresolved cited work.

Visualisation of multi-indication randomised control trial evidence to support decision-making in oncology: a case study on bevacizumab Unresolved cited work

Reference 25

Resolution
verified exact
doi, observed 2026-08-10T20:22:01.364431Z

Source-reported events for the cited work

No event found in the named queried sources as of 2026-08-11T06:34:44.6726+00:00.

source=pdf_text observed=2026-08-10T20:22:00.495623Z digest=sha256:d0efe0de9e4a21d35ecccdf0e287d1e73951715515f50457b9ed6bd66f0db056

Observation d35ee039-2697-48f3-97f9-a500496bf647 · outbound

This paper cites Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial.

Visualisation of multi-indication randomised control trial evidence to support decision-making in oncology: a case study on bevacizumab Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial

Reference 26

Resolution
verified exact
doi, observed 2026-08-10T20:22:01.353252Z

Source-reported events for the cited work

No event found in the named queried sources as of 2026-08-11T06:34:44.6726+00:00.

source=pdf_text observed=2026-08-10T20:22:00.499083Z digest=sha256:343ff02cc33308a7bac74273af2dfcf922e0770351cef4129c9e2854f4c9b6f2

Observation 2c14b25d-0d11-42c7-80ee-6eb35ebe0f30 · outbound

This paper cites an unresolved cited work.

Visualisation of multi-indication randomised control trial evidence to support decision-making in oncology: a case study on bevacizumab Unresolved cited work

Reference 27

Resolution
verified exact
doi, observed 2026-08-10T20:22:01.341235Z

Source-reported events for the cited work

No event found in the named queried sources as of 2026-08-11T06:34:44.6726+00:00.

source=pdf_text observed=2026-08-10T20:22:00.502674Z digest=sha256:a6ddaab08af2da3a0272a38cd5330d947e7e4ec5508b73af7a8622012f5b058e

Observation 503a9aa2-042b-4635-a4f8-315c7c964705 · outbound

This paper cites an unresolved cited work.

Visualisation of multi-indication randomised control trial evidence to support decision-making in oncology: a case study on bevacizumab Unresolved cited work

Reference 28

Resolution
verified exact
doi, observed 2026-08-10T20:22:01.328360Z

Source-reported events for the cited work

No event found in the named queried sources as of 2026-08-11T06:34:44.6726+00:00.

source=pdf_text observed=2026-08-10T20:22:00.506496Z digest=sha256:34f9caf452882823174a007516fa58f33e10acd8e102051fba5132f7050f3284

Observation ce23734f-6a3a-4d04-b299-df57f6fab278 · outbound

This paper cites Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (A VEX): an open- label, randomised phase 3 trial.

Visualisation of multi-indication randomised control trial evidence to support decision-making in oncology: a case study on bevacizumab Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (A VEX): an open- label, randomised phase 3 trial

Reference 29

Resolution
malformed identifier
no resolver link, observed 2026-08-10T20:22:00.510334Z

Source-reported events for the cited work

Unavailable: canonical work link unavailable.

source=pdf_text observed=2026-08-10T20:22:00.510334Z digest=sha256:32099a53f11353aa32a93d45c60ca75d135fba7f4027e1d166cc35aaf8499b12

Observation 4436beaf-1826-46bb-ad37-16f525ee1a2e · outbound

This paper cites Efficacy and safety of bevacizumab plus chemotherapy in Chinese patients with metastatic colorectal cancer: a randomized phase III ARTIST trial.

Visualisation of multi-indication randomised control trial evidence to support decision-making in oncology: a case study on bevacizumab Efficacy and safety of bevacizumab plus chemotherapy in Chinese patients with metastatic colorectal cancer: a randomized phase III ARTIST trial

Reference 30

Resolution
verified exact
doi, observed 2026-08-10T20:22:01.304038Z

Source-reported events for the cited work

No event found in the named queried sources as of 2026-08-11T06:34:44.6726+00:00.

source=pdf_text observed=2026-08-10T20:22:00.513821Z digest=sha256:6fae280ade9adc8419d5294ffd5e7362ddcfc01cf93ff26f2d3ebc9e390d0113

Observation b29e1c59-31e5-4e6b-b151-a635a5b01bf9 · outbound

This paper cites A randomized trial of bevacizumab for newly diagnosed glioblastoma.

Visualisation of multi-indication randomised control trial evidence to support decision-making in oncology: a case study on bevacizumab A randomized trial of bevacizumab for newly diagnosed glioblastoma

Reference 31

Resolution
verified exact
doi, observed 2026-08-10T20:22:01.290827Z

Source-reported events for the cited work

No event found in the named queried sources as of 2026-08-11T06:34:44.6726+00:00.

source=pdf_text observed=2026-08-10T20:22:00.517598Z digest=sha256:a1d715fc212ff05aa1c1ed917ad79471597d4f6b2661b5792c488e9e96638e4d

Observation f9a61b50-a85c-4b6b-a991-4785d12c50ac · outbound

This paper cites an unresolved cited work.

Visualisation of multi-indication randomised control trial evidence to support decision-making in oncology: a case study on bevacizumab Unresolved cited work

Reference 32

Resolution
verified exact
doi, observed 2026-08-10T20:22:01.279531Z

Source-reported events for the cited work

correction dated 2016-08-24. Source: crossref record 10.1200/jco.2016.69.6674->10.1200/jco.2015.61.5005:correction, observed 2026-07-11T02:56:59.531935+00:00. This notice travels one citation hop only.

source=pdf_text observed=2026-08-10T20:22:00.521363Z digest=sha256:b802bda9c1620ac2be527161f5d1b326fe8e9c66c4ae129a95d2158683579e43

Observation 25f584ae-1d8f-4b3e-b1f3-5b769a6ca016 · outbound

This paper cites EORTC 26101 phase III trial exploring the combination of bevacizumab and lomustine in patients with first progression of a glioblastoma.

Visualisation of multi-indication randomised control trial evidence to support decision-making in oncology: a case study on bevacizumab EORTC 26101 phase III trial exploring the combination of bevacizumab and lomustine in patients with first progression of a glioblastoma

Reference 33

Resolution
verified exact
doi, observed 2026-08-10T20:22:01.267282Z

Source-reported events for the cited work

No event found in the named queried sources as of 2026-08-11T06:34:44.6726+00:00.

source=pdf_text observed=2026-08-10T20:22:00.525180Z digest=sha256:12ca795b8bed72c6c254e92b4fee90f6d820a9a9ec8aa61001764e2322ea297b

Observation 63fe323d-f90a-46c5-bbee-e3a5af8d7ff5 · outbound

This paper cites Paclitaxel-carboplatin alone or with bevacizumab for non- small-cell lung cancer.

Visualisation of multi-indication randomised control trial evidence to support decision-making in oncology: a case study on bevacizumab Paclitaxel-carboplatin alone or with bevacizumab for non- small-cell lung cancer

Reference 34

Resolution
verified exact
doi, observed 2026-08-10T20:22:01.255140Z

Source-reported events for the cited work

No event found in the named queried sources as of 2026-08-11T06:34:44.6726+00:00.

source=pdf_text observed=2026-08-10T20:22:00.528692Z digest=sha256:82495c745cd6a958d5e7f3ae97166cd17049bf296f24dd574e46297321ba5eea

Observation 93b97b06-da19-4836-9341-25c4c268ce99 · outbound

This paper cites Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: A V Ail.

Visualisation of multi-indication randomised control trial evidence to support decision-making in oncology: a case study on bevacizumab Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: A V Ail

Reference 35

Resolution
verified exact
doi, observed 2026-08-10T20:22:01.241749Z

Source-reported events for the cited work

No event found in the named queried sources as of 2026-08-11T06:34:44.6726+00:00.

source=pdf_text observed=2026-08-10T20:22:00.533005Z digest=sha256:a314261d5536bbe0b83ab99d17dcccefe5c389a265bf03d339cdcf82a2d005c8

Observation b8f00e9e-18d2-4c3f-bcb3-bb928ff2e6ab · outbound

This paper cites an unresolved cited work.

Visualisation of multi-indication randomised control trial evidence to support decision-making in oncology: a case study on bevacizumab Unresolved cited work

Reference 36

Resolution
verified exact
doi, observed 2026-08-10T20:22:01.229113Z

Source-reported events for the cited work

No event found in the named queried sources as of 2026-08-11T06:34:44.6726+00:00.

source=pdf_text observed=2026-08-10T20:22:00.536585Z digest=sha256:a17ac3902a1e80fc07e2bd4da3699065fda6bf2deaeaf7e5c58fc829fff8367f

Observation f540eeca-2a6b-4cc6-b7fd-11ee4932a229 · outbound

This paper cites an unresolved cited work.

Visualisation of multi-indication randomised control trial evidence to support decision-making in oncology: a case study on bevacizumab Unresolved cited work

Reference 37

Resolution
unresolved
raw_fallback, observed 2026-08-10T20:22:01.694912Z

Source-reported events for the cited work

No event found in the named queried sources as of 2026-08-11T06:34:44.6726+00:00.

source=pdf_text observed=2026-08-10T20:22:00.540124Z digest=sha256:89bea29936de54a6aa6630537c35a96d407c353090c4d45b9cc9d846cdd70d8e

Observation 2926a412-04ab-4879-a995-4edd77895682 · outbound

This paper cites an unresolved cited work.

Visualisation of multi-indication randomised control trial evidence to support decision-making in oncology: a case study on bevacizumab Unresolved cited work

Reference 38

Resolution
verified exact
doi, observed 2026-08-10T20:22:01.203106Z

Source-reported events for the cited work

No event found in the named queried sources as of 2026-08-11T06:34:44.6726+00:00.

source=pdf_text observed=2026-08-10T20:22:00.548044Z digest=sha256:bdcbe584b69d2865d36252ca3cf6f74be58122c421abad556f98e4c7a24c108f

Observation 774cf3c2-e4d8-47d6-bac6-45bbeee8a6c3 · outbound

This paper cites an unresolved cited work.

Visualisation of multi-indication randomised control trial evidence to support decision-making in oncology: a case study on bevacizumab Unresolved cited work

Reference 39

Resolution
verified exact
doi, observed 2026-08-10T20:22:01.187316Z

Source-reported events for the cited work

No event found in the named queried sources as of 2026-08-11T06:34:44.6726+00:00.

source=pdf_text observed=2026-08-10T20:22:00.551713Z digest=sha256:d0148220d001d5c4bb0a08d71eb8e12d675efa3c6dbdbb2c08af4428b6d062aa

Observation 73b713b3-4080-4e17-adbe-57867d61ffba · outbound

This paper cites an unresolved cited work.

Visualisation of multi-indication randomised control trial evidence to support decision-making in oncology: a case study on bevacizumab Unresolved cited work

Reference 40

Resolution
unresolved
raw_fallback, observed 2026-08-10T20:22:01.683931Z

Source-reported events for the cited work

No event found in the named queried sources as of 2026-08-11T06:34:44.6726+00:00.

source=pdf_text observed=2026-08-10T20:22:00.555364Z digest=sha256:b34985eee43ff0fb489b65248d51b77b89f2d30072042de41115a94cb636a857

Observation ffb3556a-8fe8-42e7-8034-bfe68b561cb5 · outbound

This paper cites IMpower150 Final Overall Survival Analyses for Atezolizumab Plus Bevacizumab and Chemotherapy in First-Line Metastatic Nonsquamous NSCLC.

Visualisation of multi-indication randomised control trial evidence to support decision-making in oncology: a case study on bevacizumab IMpower150 Final Overall Survival Analyses for Atezolizumab Plus Bevacizumab and Chemotherapy in First-Line Metastatic Nonsquamous NSCLC

Reference 41

Resolution
verified exact
doi, observed 2026-08-10T20:22:01.163658Z

Source-reported events for the cited work

No event found in the named queried sources as of 2026-08-11T06:34:44.6726+00:00.

source=pdf_text observed=2026-08-10T20:22:00.563158Z digest=sha256:41bd7db0558a500af145fcc77c49260f42aebc88be9cb43ab3df48fe13aa2700

Observation 80f9434f-ab1e-4159-8f28-a3783ce6be75 · outbound

This paper cites an unresolved cited work.

Visualisation of multi-indication randomised control trial evidence to support decision-making in oncology: a case study on bevacizumab Unresolved cited work

Reference 42

Resolution
verified exact
doi, observed 2026-08-10T20:22:01.138049Z

Source-reported events for the cited work

No event found in the named queried sources as of 2026-08-11T06:34:44.6726+00:00.

source=pdf_text observed=2026-08-10T20:22:00.566457Z digest=sha256:2ada00c457804d78e7e153684d50d08db056615513ff660260457fa7a252dc62

Observation e5ab4c71-72ac-4a72-8229-1bece14f149a · outbound

This paper cites an unresolved cited work.

Visualisation of multi-indication randomised control trial evidence to support decision-making in oncology: a case study on bevacizumab Unresolved cited work

Reference 43

Resolution
verified exact
doi, observed 2026-08-10T20:22:00.695676Z

Source-reported events for the cited work

No event found in the named queried sources as of 2026-08-11T06:34:44.6726+00:00.

source=pdf_text observed=2026-08-10T20:22:00.569466Z digest=sha256:c086ecb7a185003218d642b1396e6e2861c9fb27a65515f6eb0c66ea0c1981b2

Observation ef0672ab-8495-461f-adc8-c136e06276e0 · outbound

This paper cites Incorporation of bevacizumab in the primary treatment of ovarian cancer.

Visualisation of multi-indication randomised control trial evidence to support decision-making in oncology: a case study on bevacizumab Incorporation of bevacizumab in the primary treatment of ovarian cancer

Reference 44

Resolution
verified exact
doi, observed 2026-08-10T20:22:01.107182Z

Source-reported events for the cited work

No event found in the named queried sources as of 2026-08-11T06:34:44.6726+00:00.

source=pdf_text observed=2026-08-10T20:22:00.572456Z digest=sha256:556ceb2e2d59906f424214cae510d3e104d06bbe1565f9e1c38cce5d7752c2ba

Observation a0ff79dc-c504-4599-8309-9d105b722830 · outbound

This paper cites Final Overall Survival of a Randomized Trial of Bevacizumab for Primary Treatment of Ovarian Cancer.

Visualisation of multi-indication randomised control trial evidence to support decision-making in oncology: a case study on bevacizumab Final Overall Survival of a Randomized Trial of Bevacizumab for Primary Treatment of Ovarian Cancer

Reference 45

Resolution
verified exact
doi, observed 2026-08-10T20:22:01.090622Z

Source-reported events for the cited work

No event found in the named queried sources as of 2026-08-11T06:34:44.6726+00:00.

source=pdf_text observed=2026-08-10T20:22:00.575341Z digest=sha256:bc22acfaeae1c898b8d0acefeada31948dcbe869bb1d06871d97a94271293be8

Observation beb30c89-3aec-46f7-b928-c0739a6fccec · outbound

This paper cites A phase 3 trial of bevacizumab in ovarian cancer.

Visualisation of multi-indication randomised control trial evidence to support decision-making in oncology: a case study on bevacizumab A phase 3 trial of bevacizumab in ovarian cancer

Reference 46

Resolution
verified exact
doi, observed 2026-08-10T20:22:01.077249Z

Source-reported events for the cited work

No event found in the named queried sources as of 2026-08-11T06:34:44.6726+00:00.

source=pdf_text observed=2026-08-10T20:22:00.578249Z digest=sha256:d5d6ecbfb2f21addae8801f772252381262df16fffae77f75955817cf36b6361

Observation 33fdf2ed-9e25-4640-8fa7-5ecc9119333f · outbound

This paper cites Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): Overall survival results of a phase 3 randomised trial.

Visualisation of multi-indication randomised control trial evidence to support decision-making in oncology: a case study on bevacizumab Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): Overall survival results of a phase 3 randomised trial

Reference 47

Resolution
verified exact
doi, observed 2026-08-10T20:22:01.056962Z

Source-reported events for the cited work

No event found in the named queried sources as of 2026-08-11T06:34:44.6726+00:00.

source=pdf_text observed=2026-08-10T20:22:00.581548Z digest=sha256:2dbdcbc94c1d60513116722e9be9f22e5f4e5b8585e388585e10dcf60ad02ba5

Observation 616b779f-11da-44c7-9eec-f9f141a740a4 · outbound

This paper cites an unresolved cited work.

Visualisation of multi-indication randomised control trial evidence to support decision-making in oncology: a case study on bevacizumab Unresolved cited work

Reference 48

Resolution
verified exact
doi, observed 2026-08-10T20:22:01.043126Z

Source-reported events for the cited work

No event found in the named queried sources as of 2026-08-11T06:34:44.6726+00:00.

source=pdf_text observed=2026-08-10T20:22:00.584354Z digest=sha256:551c5f65476f7fdb78a89eea1c061a959cd14dd262eed29eafba44605a2781d8

Observation 2fe6f5c1-7d67-43c8-9f06-35d13417f996 · outbound

This paper cites Final overall survival and safety analysis of OCEANS, a phase 3 trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent ovarian cancer.

Visualisation of multi-indication randomised control trial evidence to support decision-making in oncology: a case study on bevacizumab Final overall survival and safety analysis of OCEANS, a phase 3 trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent ovarian cancer

Reference 49

Resolution
verified exact
doi, observed 2026-08-10T20:22:01.029087Z

Source-reported events for the cited work

No event found in the named queried sources as of 2026-08-11T06:34:44.6726+00:00.

source=pdf_text observed=2026-08-10T20:22:00.587526Z digest=sha256:67aa281e1f0bcf5d8983ab2d8631faa5ed8a49cd8889df9641e0a11080f3da00

Observation 5d682c8c-2b78-4e9e-a0f7-6fba75ffd206 · outbound

This paper cites an unresolved cited work.

Visualisation of multi-indication randomised control trial evidence to support decision-making in oncology: a case study on bevacizumab Unresolved cited work

Reference 50

Resolution
verified exact
doi, observed 2026-08-10T20:22:00.682714Z

Source-reported events for the cited work

No event found in the named queried sources as of 2026-08-11T06:34:44.6726+00:00.

source=pdf_text observed=2026-08-10T20:22:00.590311Z digest=sha256:cad73a17778f65e06aff9e43e5e9358206936caa3531f6f3814ac83e81518f8b

Observation eeedaa85-d612-4ac4-a05e-4883d1678511 · outbound

This paper cites Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial.

Visualisation of multi-indication randomised control trial evidence to support decision-making in oncology: a case study on bevacizumab Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial

Reference 51

Resolution
verified exact
doi, observed 2026-08-10T20:22:01.009857Z

Source-reported events for the cited work

No event found in the named queried sources as of 2026-08-11T06:34:44.6726+00:00.

source=pdf_text observed=2026-08-10T20:22:00.593626Z digest=sha256:4cd5233127b3634dc3f75d8e4a0028488fce82679ff15ac69de2f2f74a5c1007

Observation 40d45e4e-65b4-4903-96f4-d292fa73c85c · outbound

This paper cites Bevacizumab with or after chemotherapy for platinum- resistant recurrent ovarian cancer: exploratory analyses of the AURELIA trial.

Visualisation of multi-indication randomised control trial evidence to support decision-making in oncology: a case study on bevacizumab Bevacizumab with or after chemotherapy for platinum- resistant recurrent ovarian cancer: exploratory analyses of the AURELIA trial

Reference 52

Resolution
verified exact
doi, observed 2026-08-10T20:22:00.998021Z

Source-reported events for the cited work

No event found in the named queried sources as of 2026-08-11T06:34:44.6726+00:00.

source=pdf_text observed=2026-08-10T20:22:00.596683Z digest=sha256:7d0ee6c8eed0a87c7be1a25e86c0b05e10ba358415292bb581e0d8668fe14428

Observation afc67627-1073-45a6-980b-ed0a984e9212 · outbound

This paper cites an unresolved cited work.

Visualisation of multi-indication randomised control trial evidence to support decision-making in oncology: a case study on bevacizumab Unresolved cited work

Reference 53

Resolution
verified exact
doi, observed 2026-08-10T20:22:00.986892Z

Source-reported events for the cited work

No event found in the named queried sources as of 2026-08-11T06:34:44.6726+00:00.

source=pdf_text observed=2026-08-10T20:22:00.599646Z digest=sha256:5e1865b244bde6d69a9d73191a8f434008b1ccbf3abaaaa0320707bdc1f57857

Observation 99c06af9-c50d-4fe4-b96a-461b67d8c5fe · outbound

This paper cites A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer.

Visualisation of multi-indication randomised control trial evidence to support decision-making in oncology: a case study on bevacizumab A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer

Reference 54

Resolution
verified exact
doi, observed 2026-08-10T20:22:00.975600Z

Source-reported events for the cited work

No event found in the named queried sources as of 2026-08-11T06:34:44.6726+00:00.

source=pdf_text observed=2026-08-10T20:22:00.602952Z digest=sha256:8b6f8e07171e53622c5df4cafb8687e93c79d17522e880b3860f80d9ec65ab2a

Observation 4155ebfc-98c7-49d2-88f3-efaf3b2552f9 · outbound

This paper cites an unresolved cited work.

Visualisation of multi-indication randomised control trial evidence to support decision-making in oncology: a case study on bevacizumab Unresolved cited work

Reference 55

Resolution
verified exact
doi, observed 2026-08-10T20:22:01.491748Z

Source-reported events for the cited work

No event found in the named queried sources as of 2026-08-11T06:34:44.6726+00:00.

source=pdf_text observed=2026-08-10T20:22:00.170206Z digest=sha256:8286b15c5ad88cc529138ac21604042a218302e173007e4d3833ddc889defee7

Observation 98904ff8-be65-4106-9cab-a44af26949c0 · outbound

This paper cites Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240).

Visualisation of multi-indication randomised control trial evidence to support decision-making in oncology: a case study on bevacizumab Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240)

Reference 59

Resolution
verified exact
doi, observed 2026-08-10T20:22:01.447499Z

Source-reported events for the cited work

No event found in the named queried sources as of 2026-08-11T06:34:44.6726+00:00.

source=pdf_text observed=2026-08-10T20:22:00.189211Z digest=sha256:ddce5362fce798010ce5ed9587c0ac8462b9f484d46aea518db0eba57f0ef860

Observation 873f2042-e766-4a01-94ad-d376fc5d8c72 · outbound

This paper cites Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.

Visualisation of multi-indication randomised control trial evidence to support decision-making in oncology: a case study on bevacizumab Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

Reference 62

Resolution
unresolved
no resolver link, observed 2026-08-10T20:22:00.202876Z

Source-reported events for the cited work

Unavailable: canonical work link unavailable.

source=pdf_text observed=2026-08-10T20:22:00.202876Z digest=sha256:9287a8e183fbc57fc6dc0a08c6d09ddadacc44dfeaea9b2ce95ace8a8326ea39

Observation 3988e2f6-8d43-4544-ab6b-865cc525d2de · outbound

This paper cites Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (A VEX): an open-label, randomised phase 3 trial.

Visualisation of multi-indication randomised control trial evidence to support decision-making in oncology: a case study on bevacizumab Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (A VEX): an open-label, randomised phase 3 trial

Reference 70

Resolution
verified exact
doi, observed 2026-08-10T20:22:01.316275Z

Source-reported events for the cited work

No event found in the named queried sources as of 2026-08-11T06:34:44.6726+00:00.

source=pdf_text observed=2026-08-10T20:22:00.240808Z digest=sha256:45ed2c2fa950063d9ef9af4d15b2864a26d94e9490d4232fc131e7d9c919de58

Observation 6155dce0-8e60-4668-9e94-4a399fe45688 · outbound

This paper cites an unresolved cited work.

Visualisation of multi-indication randomised control trial evidence to support decision-making in oncology: a case study on bevacizumab Unresolved cited work

Reference 73

Resolution
unresolved
raw_fallback, observed 2026-08-10T20:22:01.773693Z

Source-reported events for the cited work

No event found in the named queried sources as of 2026-08-11T06:34:44.6726+00:00.

source=pdf_text observed=2026-08-10T20:22:00.252930Z digest=sha256:897de3e8c4b4b7bb5b2c5299d4088818cb977cb5e2254f7f3bf8cfc38bece4d1

Observation 409297a9-ee90-49c3-a43a-9435ddd42f80 · outbound

This paper cites an unresolved cited work.

Visualisation of multi-indication randomised control trial evidence to support decision-making in oncology: a case study on bevacizumab Unresolved cited work

Reference 81

Resolution
malformed identifier
no resolver link, observed 2026-08-10T20:22:00.289765Z

Source-reported events for the cited work

Unavailable: canonical work link unavailable.

source=pdf_text observed=2026-08-10T20:22:00.289765Z digest=sha256:5ea2700880fb7cd4c6c1c388319e3c57357b8fff8969e6e2b187a7154eb1916f

Observation 1fe2a228-e35e-48a7-a1b6-228b852bcee0 · outbound

This paper cites an unresolved cited work.

Visualisation of multi-indication randomised control trial evidence to support decision-making in oncology: a case study on bevacizumab Unresolved cited work

Reference 84

Resolution
malformed identifier
doi_truncated, observed 2026-08-10T20:22:01.122158Z

Source-reported events for the cited work

No event found in the named queried sources as of 2026-08-11T06:34:44.6726+00:00.

source=pdf_text observed=2026-08-10T20:22:00.301707Z digest=sha256:32398ba678c792fd1927ab647dac663ea80e30a971088da5134b213d04daad6c

Observation a3b6001f-9cb2-4c88-889c-c53a7b012590 · outbound

This paper cites Randomized Phase III Trial of Gemcitabine and Cisplatin With Bevacizumab or Placebo in Patients With Advanced 30 Urothelial Carcinoma: Results of CALGB 90601 (Alliance).

Visualisation of multi-indication randomised control trial evidence to support decision-making in oncology: a case study on bevacizumab Randomized Phase III Trial of Gemcitabine and Cisplatin With Bevacizumab or Placebo in Patients With Advanced 30 Urothelial Carcinoma: Results of CALGB 90601 (Alliance)

Reference 103

Resolution
verified fuzzy
raw_fallback, observed 2026-08-10T20:22:01.763297Z

Source-reported events for the cited work

No event found in the named queried sources as of 2026-08-11T06:34:44.6726+00:00.

source=pdf_text observed=2026-08-10T20:22:00.375895Z digest=sha256:9f4a3087419ff3845ad8b58c8dc52b30375c582f22bea79458a5d8c6915ebc87

Observation e085776d-211b-479e-9a2b-7b079a9ecc99 · outbound

This paper cites On weakly informative prior distributions for the heterogeneity parameter in Bayesian random‐effects meta‐analysis.

Visualisation of multi-indication randomised control trial evidence to support decision-making in oncology: a case study on bevacizumab On weakly informative prior distributions for the heterogeneity parameter in Bayesian random‐effects meta‐analysis

Reference 106

Resolution
verified fuzzy
raw_fallback, observed 2026-08-10T20:22:01.751966Z

Source-reported events for the cited work

No event found in the named queried sources as of 2026-08-11T06:34:44.6726+00:00.

source=pdf_text observed=2026-08-10T20:22:00.389258Z digest=sha256:bf0ad8c51afe134dd0b0211db78de631e2c7471811028dcf4c2d26673f9b1583

Observation 82774529-ebd5-4a9a-a670-533aef9986c1 · outbound

This paper cites Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer.

Visualisation of multi-indication randomised control trial evidence to support decision-making in oncology: a case study on bevacizumab Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer

Reference 107

Resolution
verified exact
doi, observed 2026-08-10T20:22:00.856845Z

Source-reported events for the cited work

No event found in the named queried sources as of 2026-08-11T06:34:44.6726+00:00.

source=pdf_text observed=2026-08-10T20:22:00.406266Z digest=sha256:255e1b0869adaf0f893403258edf7750c272dffcdb2334fd67af817bd1e6a642

Observation 8dd591cd-be97-4c42-9f78-465907be9623 · outbound

This paper cites Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer.

Visualisation of multi-indication randomised control trial evidence to support decision-making in oncology: a case study on bevacizumab Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer

Reference 108

Resolution
verified exact
doi, observed 2026-08-10T20:22:00.844662Z

Source-reported events for the cited work

No event found in the named queried sources as of 2026-08-11T06:34:44.6726+00:00.

source=pdf_text observed=2026-08-10T20:22:00.410045Z digest=sha256:53d00a1703632e7b22db10818b002a1612cb651a58580877b67c52e390cf4a80

Observation 8606b344-9d2c-432e-bbc5-1b99b083846a · outbound

This paper cites Bevacizumab in the first-line treatment of metastatic breast cancer.

Visualisation of multi-indication randomised control trial evidence to support decision-making in oncology: a case study on bevacizumab Bevacizumab in the first-line treatment of metastatic breast cancer

Reference 109

Resolution
verified exact
doi, observed 2026-08-10T20:22:00.831065Z

Source-reported events for the cited work

No event found in the named queried sources as of 2026-08-11T06:34:44.6726+00:00.

source=pdf_text observed=2026-08-10T20:22:00.413732Z digest=sha256:6c40bb3110e31852e06a7cdb174deea3c4013bb09a864eb9e7ab49f445fe1d8f

Observation 0eb3da54-2e89-46f4-87d8-989b83003e47 · outbound

This paper cites Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206.

Visualisation of multi-indication randomised control trial evidence to support decision-making in oncology: a case study on bevacizumab Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206

Reference 115

Resolution
verified exact
doi, observed 2026-08-10T20:22:00.963962Z

Source-reported events for the cited work

No event found in the named queried sources as of 2026-08-11T06:34:44.6726+00:00.

source=pdf_text observed=2026-08-10T20:22:00.606253Z digest=sha256:84e80282d5df531d081ad0410a7fe22ebb484a497d79011386a312ce2a3399cc

Observation 34ec7524-e127-4126-a769-4aa6643018b3 · outbound

This paper cites Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206.

Visualisation of multi-indication randomised control trial evidence to support decision-making in oncology: a case study on bevacizumab Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206

Reference 116

Resolution
verified exact
doi, observed 2026-08-10T20:22:00.951885Z

Source-reported events for the cited work

No event found in the named queried sources as of 2026-08-11T06:34:44.6726+00:00.

source=pdf_text observed=2026-08-10T20:22:00.609256Z digest=sha256:ae7c7cf99e3fb28aadb45e6bd980ea80a7e8f898e5827dfc5c97c2a12d7b6e3b

Observation c609bc6f-6896-4855-8fd0-83b61b23c008 · outbound

This paper cites Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial.

Visualisation of multi-indication randomised control trial evidence to support decision-making in oncology: a case study on bevacizumab Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial

Reference 117

Resolution
verified fuzzy
raw_fallback, observed 2026-08-10T20:22:01.672546Z

Source-reported events for the cited work

No event found in the named queried sources as of 2026-08-11T06:34:44.6726+00:00.

source=pdf_text observed=2026-08-10T20:22:00.612286Z digest=sha256:6be43800114f524f113c001596afa62b076a7eb0b2f0a93f559ee39e33a00020

Observation 17a47edf-fe0c-4c2c-9eed-69517b6d054a · outbound

This paper cites Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (A VOREN): final analysis of overall survival.

Visualisation of multi-indication randomised control trial evidence to support decision-making in oncology: a case study on bevacizumab Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (A VOREN): final analysis of overall survival

Reference 119

Resolution
verified exact
doi, observed 2026-08-10T20:22:00.927619Z

Source-reported events for the cited work

No event found in the named queried sources as of 2026-08-11T06:34:44.6726+00:00.

source=pdf_text observed=2026-08-10T20:22:00.618159Z digest=sha256:dfbfa40e93ed426d750b72011739b71c8bd493dbeea61d2db57d8c311b39baa9

Observation fb0f8d45-6448-4fa3-8ed4-ab5c18d1fbe6 · outbound

This paper cites an unresolved cited work.

Visualisation of multi-indication randomised control trial evidence to support decision-making in oncology: a case study on bevacizumab Unresolved cited work

Reference 120

Resolution
verified exact
doi, observed 2026-08-10T20:22:00.916610Z

Source-reported events for the cited work

No event found in the named queried sources as of 2026-08-11T06:34:44.6726+00:00.

source=pdf_text observed=2026-08-10T20:22:00.621194Z digest=sha256:55f697134742a67c98c5aa53e620a5199acb386276595871213f7efa2a74389a

Observation 006bf548-801e-472d-ae2d-cfbb48b0664f · outbound

This paper cites Bevacizumab in combination with chemotherapy as first- line therapy in advanced gastric cancer: A randomized, double-blind, placebo-controlled phase III study.

Visualisation of multi-indication randomised control trial evidence to support decision-making in oncology: a case study on bevacizumab Bevacizumab in combination with chemotherapy as first- line therapy in advanced gastric cancer: A randomized, double-blind, placebo-controlled phase III study

Reference 121

Resolution
verified exact
doi, observed 2026-08-10T20:22:00.905920Z

Source-reported events for the cited work

No event found in the named queried sources as of 2026-08-11T06:34:44.6726+00:00.

source=pdf_text observed=2026-08-10T20:22:00.623971Z digest=sha256:6a311bfdad52878df34b587af598eda601015f6a18baaa07e5dcaab9bee2a101

Observation f7bf03a2-2a2e-4af2-86bc-b98ae90bef06 · outbound

This paper cites R-CHOP with or without bevacizumab in patients with previously untreated diffuse large B-cell lymphoma: Final MAIN study outcomes.

Visualisation of multi-indication randomised control trial evidence to support decision-making in oncology: a case study on bevacizumab R-CHOP with or without bevacizumab in patients with previously untreated diffuse large B-cell lymphoma: Final MAIN study outcomes

Reference 122

Resolution
metadata mismatch
raw_fallback, observed 2026-08-10T20:22:01.618955Z

Source-reported events for the cited work

No event found in the named queried sources as of 2026-08-11T06:34:44.6726+00:00.

source=pdf_text observed=2026-08-10T20:22:00.626726Z digest=sha256:4e59ef58a3e540a27600e254be03018fc6a29500a95bf8d98494f91a8ea8c030

Observation 9e59c117-db0b-4037-8d00-0b0f55ad0109 · outbound

This paper cites Randomized Phase III Trial of Gemcitabine and Cisplatin With Bevacizumab or Placebo in Patients With Advanced Urothelial Carcinoma: Results of CALGB 90601 (Alliance).

Visualisation of multi-indication randomised control trial evidence to support decision-making in oncology: a case study on bevacizumab Randomized Phase III Trial of Gemcitabine and Cisplatin With Bevacizumab or Placebo in Patients With Advanced Urothelial Carcinoma: Results of CALGB 90601 (Alliance)

Reference 123

Resolution
verified exact
doi, observed 2026-08-10T20:22:00.892970Z

Source-reported events for the cited work

No event found in the named queried sources as of 2026-08-11T06:34:44.6726+00:00.

source=pdf_text observed=2026-08-10T20:22:00.630140Z digest=sha256:bd63b8069ffc3b4895190c8b32c48292885dab85184d0510fa5a003807b943a5

Observation f7facc4d-9b14-44cc-8534-00e3fca312dc · outbound

This paper cites an unresolved cited work.

Visualisation of multi-indication randomised control trial evidence to support decision-making in oncology: a case study on bevacizumab Unresolved cited work

Reference 124

Resolution
unresolved
raw_fallback, observed 2026-08-10T20:22:01.660315Z

Source-reported events for the cited work

No event found in the named queried sources as of 2026-08-11T06:34:44.6726+00:00.

source=pdf_text observed=2026-08-10T20:22:00.633481Z digest=sha256:1ce86389c67f3f7441ee0310cd61c72c38b14e2a4d5cc46b8d57fe1bacdadacf

Observation 711aa054-97f6-4458-9545-26827acdc170 · outbound

This paper cites an unresolved cited work.

Visualisation of multi-indication randomised control trial evidence to support decision-making in oncology: a case study on bevacizumab Unresolved cited work

Reference 126

Resolution
verified exact
doi, observed 2026-08-10T20:22:00.867601Z

Source-reported events for the cited work

No event found in the named queried sources as of 2026-08-11T06:34:44.6726+00:00.

source=pdf_text observed=2026-08-10T20:22:00.640113Z digest=sha256:ef20cc43b8d2c4d9b9f92194e36d7409fe551bbd99d539878b19c54f0bc96c41

Observation 49b953c8-be43-4a58-99dc-37a67a51182d · outbound

This paper cites Bayesian methods in meta-analysis and evidence synthesis.

Visualisation of multi-indication randomised control trial evidence to support decision-making in oncology: a case study on bevacizumab Bayesian methods in meta-analysis and evidence synthesis

Reference 127

Resolution
verified fuzzy
raw_fallback, observed 2026-08-10T20:22:01.648786Z

Source-reported events for the cited work

No event found in the named queried sources as of 2026-08-11T06:34:44.6726+00:00.

source=pdf_text observed=2026-08-10T20:22:00.643214Z digest=sha256:f5055b7d3ab721172097e282cd85459167d388b1ec1bb3e839d49643bfc47d9b

Observation f9d59e0e-422f-40cf-95d3-3da100260b59 · outbound

This paper cites On weakly informative prior distributions for the heterogeneity parameter in Bayesian random‐effects meta‐analysis.

Visualisation of multi-indication randomised control trial evidence to support decision-making in oncology: a case study on bevacizumab On weakly informative prior distributions for the heterogeneity parameter in Bayesian random‐effects meta‐analysis

Reference 128

Resolution
verified fuzzy
raw_fallback, observed 2026-08-10T20:22:01.633009Z

Source-reported events for the cited work

No event found in the named queried sources as of 2026-08-11T06:34:44.6726+00:00.

source=pdf_text observed=2026-08-10T20:22:00.646949Z digest=sha256:10417ba765c60b0842cd2244db97f4d4191c6929ab09011cd6c69f83abb52ff7

Observation 69fe44ee-0d37-4f82-b583-06018e308e5b · outbound

This paper cites DOI: 10.1016/s2213-2600(19)30084-0.

Visualisation of multi-indication randomised control trial evidence to support decision-making in oncology: a case study on bevacizumab DOI: 10.1016/s2213-2600(19)30084-0

Reference 401

Resolution
verified exact
doi, observed 2026-08-10T20:22:00.708404Z

Source-reported events for the cited work

No event found in the named queried sources as of 2026-08-11T06:34:44.6726+00:00.

source=pdf_text observed=2026-08-10T20:22:00.559041Z digest=sha256:02d4aba34937b164c140cf99256c72e113493e317743314e2141c1c107513296

Observation 373f3541-b6fb-4c7c-b492-59b2811c888f · outbound

This paper cites DOI: 10.1016/s1470-2045(14)70381-x.

Visualisation of multi-indication randomised control trial evidence to support decision-making in oncology: a case study on bevacizumab DOI: 10.1016/s1470-2045(14)70381-x

Reference 1244

Resolution
verified exact
doi, observed 2026-08-10T20:22:01.216069Z

Source-reported events for the cited work

correction dated 2014-09-30. Source: crossref record 10.1016/s1470-2045(14)70506-6->10.1016/s1470-2045(14)70381-x:correction, observed 2026-07-11T03:14:07.972603+00:00. This notice travels one citation hop only.

source=pdf_text observed=2026-08-10T20:22:00.543875Z digest=sha256:d99c6e8f973e996a54947829b8fc617559ae465aae873aaf2379a2f3c3bd8ff2

Observation 3dba0e75-b4f3-4c49-a927-1623ca5480b0 · outbound

This paper cites an unresolved cited work.

Visualisation of multi-indication randomised control trial evidence to support decision-making in oncology: a case study on bevacizumab Unresolved cited work

Reference 1540

Resolution
verified exact
doi, observed 2026-08-10T20:22:00.879637Z

Source-reported events for the cited work

No event found in the named queried sources as of 2026-08-11T06:34:44.6726+00:00.

source=pdf_text observed=2026-08-10T20:22:00.636969Z digest=sha256:5c5bac9afb9eeb12e4a106c97d3a2b108311c0bfe509c1be8827724521cb12d6

Observation bd52ef17-eb81-4ae2-aee2-23ffe933c46e · outbound

This paper cites an unresolved cited work.

Visualisation of multi-indication randomised control trial evidence to support decision-making in oncology: a case study on bevacizumab Unresolved cited work

Reference 2111

Resolution
verified exact
doi, observed 2026-08-10T20:22:00.939515Z

Source-reported events for the cited work

No event found in the named queried sources as of 2026-08-11T06:34:44.6726+00:00.

source=pdf_text observed=2026-08-10T20:22:00.615105Z digest=sha256:1c37d9ad15b81fcd8faafa20c63f9b75cbd32165d10197bcb9fd90ddcb0771a7

Pith citing papers

No inbound Pith citation observations are available.